Literature DB >> 21077033

[The new TNM classification in lung cancer].

Anna Wrona1, Jacek Jassem.   

Abstract

This paper presents the new TNM classification in lung cancer and its history. Seventh edition of tumor, node, metastasis (TNM) classification in lung cancer has been published by the International Union Against Cancer (UICC) and the American Joint Committee on Cancer (AJCC) at the beginning of 2009. The changes were based upon the results of the international project of the International Association for the Study of Lung Cancer (IASLC). The database included 81.495 patients from the entire world (68.463 with non-small cell lung cancer and 13.032 with small cell lung cancer) treated with various modalities between 1990 and 2000. The collected data were validated internally and externally. The tumor size was considered of prognostic relevance: T1 tumors were subdivided into T1a (≤ 2 cm) and T1b (〉 2 cm - ≤ 3 cm), T2 tumors into T2a (〉 3 cm - ≤ 5 cm) and T2b (〉 5 cm - ≤ 7 cm), and T2 tumors 〉 7 cm were reclassified as T3. Tumors with the additional nodules in the same lobe as the primary tumor were classified as T3, those with additional nodules in another ipsilateral lobe - as T4. There were no changes in N category. In the M category, M1 was subclassified into M1a (contralateral lung nodules and pleural dissemination) and M1b (distant metastasis). Large T2 tumors (T2bN0M0) were upstaged from IB to IIA, small T2 tumors (T2aN1M0) were downstaged from the IIB to IIA and T4N0-N1M0 - from IIIB to IIIA. The TNM classification was also recommended for small cell lung cancer instead of previously used categories of limited and extensive disease.

Entities:  

Mesh:

Year:  2010        PMID: 21077033

Source DB:  PubMed          Journal:  Pneumonol Alergol Pol        ISSN: 0867-7077


  12 in total

1.  Predictive value of 18F-fluorodeoxyglucose positron emission tomography - computed tomography compared to postoperative pathological findings for patients with non-small-cell lung cancer.

Authors:  Jie Xue; Jinsong Zheng; Hongbo Guo; Xiaohui Wang; Anqin Han
Journal:  Mol Clin Oncol       Date:  2014-09-04

2.  Lipopolysaccharide-binding protein is efficient in biodosimetry during radiotherapy of lung cancer.

Authors:  Justyna Chalubinska-Fendler; Wojciech Fendler; Michal Spych; Krystyna Wyka; Jolanta Luniewska-Bury; Jacek Fijuth
Journal:  Biomed Rep       Date:  2016-08-08

3.  Classification of lung cancer tumors based on structural and physicochemical properties of proteins by bioinformatics models.

Authors:  Faezeh Hosseinzadeh; Mansour Ebrahimi; Bahram Goliaei; Narges Shamabadi
Journal:  PLoS One       Date:  2012-07-19       Impact factor: 3.240

4.  Clinical investigation into the initial diagnosis and treatment of 1,168 lung cancer patients.

Authors:  Qian Shao; Jianbin Li; Fengxiang Li; Suzhen Wang; Wei Wang; Shanshan Liu; Yingjie Zhang
Journal:  Oncol Lett       Date:  2014-12-08       Impact factor: 2.967

5.  Lung adenocarcinoma harboring L858R and T790M mutations in epidermal growth factor receptor, with poor response to gefitinib: A case report.

Authors:  Yue Feng Wang; Xianhong Xiang; Xiaojuan Pei; Shuhua Li; Cuilan Tang; Liantang Wang; Zun-Fu Ke
Journal:  Oncol Lett       Date:  2014-07-04       Impact factor: 2.967

6.  Overexpression of miR-758 inhibited proliferation, migration, invasion, and promoted apoptosis of non-small cell lung cancer cells by negatively regulating HMGB.

Authors:  Guo-Hua Zhou; Yi-Yu Lu; Jing-Lian Xie; Zi-Kun Gao; Xiao-Bo Wu; Wei-Shen Yao; Wei-Guang Gu
Journal:  Biosci Rep       Date:  2019-01-18       Impact factor: 3.840

7.  Improved classification of lung cancer tumors based on structural and physicochemical properties of proteins using data mining models.

Authors:  R Geetha Ramani; Shomona Gracia Jacob
Journal:  PLoS One       Date:  2013-03-07       Impact factor: 3.240

8.  Ku80 is highly expressed in lung adenocarcinoma and promotes cisplatin resistance.

Authors:  Qingshan Ma; Ping Li; Minyu Xu; Jinzhi Yin; Zhenzhong Su; Wei Li; Jie Zhang
Journal:  J Exp Clin Cancer Res       Date:  2012-11-27

9.  [Clinical Assessment of Chemosensitivity Test in Xeno-free Culture of Autologous 
Malignant Effusion Cells from Patients with Advanced Lung Adenocarcinoma].

Authors:  Liang Chen; Shunfang Yang; Jinqi Jiang; Ying Zhang; Hui Feng; Jie Cao; Xinyue Ge; Wenhui Xie
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2016-09-20

10.  MicroRNA-373 Inhibits Cell Proliferation and Invasion via Targeting BRF2 in Human Non-small Cell Lung Cancer A549 Cell Line.

Authors:  Lei Wang; Junfeng Qu; Li Zhou; Fei Liao; Ju Wang
Journal:  Cancer Res Treat       Date:  2017-10-12       Impact factor: 4.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.